Clozapine is a much underused drug, due to lack of promotion by pharmaceutical companies and patient and prescriber fears of clozapine-related risks. The course fills this lacuna and teaches indication of patients for clozapine treatment (treatment refractory schizophrenia and off-label use), motivating patients for clozapine, preparation of the treatment, titration of clozapine, monitoring of clozapine plasmalevel and granulocyte counts, assessment and treatment of frequent and rare side effects, and weighing arguments for and against compulsory treatment and stopping granulocyte controls. Brief powerpoint presentations and video's will be alternated with discussions. Course director Schulte proposes to include a third course director: Dr. J. Bogers, M.D., who is a board member of the Dutch Collaboration Group too, and has been involved in many educational and scientific activities of the collaboration group.